Twelve-Month Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease

Journal of Endovascular Therapy

Volumn 23, Issue 5, 2016, Pages 701-707

  Müller Hülsbeck, Stefan ^a   Keirse, Koen ^b   Zeller, Thomas ^c   Schroë, Herman ^d   Diaz Cartelle, Juan ^e  

^a Ev Luth Diakonissenanstalt Flensburg ^*  (Germany)

^b Regionaal Ziekenhuis Heilig Hart Tienen   (Belgium)

^c UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Belgium)

^e BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

claudication; drug eluting stent; paclitaxel; peripheral artery disease; popliteal artery; restenosis; superficial femoral artery; target lesion revascularization

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN; ALLOY; CARDIOVASCULAR AGENT; NITINOL; PACLITAXEL;

AGED; ANGIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CLAUDICATION; CLINICAL TRIAL; DRUG ELUTING STENT; FEMALE; HUMAN; LEG ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSTRUCTIVE FEMOROPOPLITEAL DISEASE; PACLITAXEL ELUTING STENT; PEAK SYSTOLIC VELOCITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY VASCULAR OBSTRUCTIVE DISEASE; REVASCULARIZATION; STENT THROMBOSIS; ANKLE BRACHIAL INDEX; AUSTRALIA; BLOOD FLOW; BLOOD FLOW VELOCITY; CHRONIC DISEASE; DEVICES; DIAGNOSTIC IMAGING; DUPLEX DOPPLER ULTRASONOGRAPHY; ENDOVASCULAR SURGERY; EUROPE; FEMORAL ARTERY; ISCHEMIA; KAPLAN MEIER METHOD; LIMB SALVAGE; MIDDLE AGED; NEW ZEALAND; PATHOPHYSIOLOGY; PROSTHESIS DESIGN; SELF EXPANDABLE METALLIC STENT; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME FACTOR; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; ALLOYS; ANKLE BRACHIAL INDEX; AUSTRALIA; BLOOD FLOW VELOCITY; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; EUROPE; FEMALE; FEMORAL ARTERY; HUMANS; ISCHEMIA; KAPLAN-MEIER ESTIMATE; LIMB SALVAGE; MALE; MIDDLE AGED; NEW ZEALAND; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGIONAL BLOOD FLOW; SELF EXPANDABLE METALLIC STENTS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR PATENCY;

EID: 85009070649     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602816650206     Document Type: Article

References (29)

1. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006; 354: 1879-1888.
2. Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation. 2007; 116: 285-292.
3. Bosiers M, Deloose K, Callaert J, et al. 4-French-compatible endovascular material is safe and effective in the treatment of femoropopliteal occlusive disease: results of the 4-EVER trial. J Endovasc Ther. 2013; 20: 746-756.
4. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012; 19: 1-9.
5. IDEV. Supera Peripheral Stent System SSED (SUPERB). 2014. http://www.accessdata.fda.gov/cdrh-docs/pdf12/P120020b.pdf.
6. Laird JR, Jain A, Zeller T, et al. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the Complete SE multicenter trial. J Endovasc Ther. 2014; 21: 202-212.
7. Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009; 16: 261-269.
8. Cordis. SMART CONTROL SSED (STROLL). 2012. http://www.accessdata.fda.gov/cdrh-docs/pdf12/P120002b.pdf.
9. Matsumura JS, Yamanouchi D, Goldstein JA, et al. The United States study for evaluating endovascular treatments of lesions in the superficial femoral artery and proximal popliteal by using the Protege Everflex nitinol stent system II (DURABILITY II). J Vasc Surg. 2013; 58: 73-83. e1.
10. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011; 4: 495-504.
11. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013; 61: 2417-2427.
12. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997; 96: 636-645.
13. Wiskirchen J, Schober W, Schart N, et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol. 2004; 39: 565-571.
14. Costa MA, Simon DI., Molecular basis of restenosis and drug-eluting stents. Circulation. 2005; 111: 2257-2273.
15. Forrester JS, Fishbein M, Helfant R, et al. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991; 17: 758-769.
16. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997; 26: 517-538.
17. Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011; 57: 1700-1708.
18. Wilson GJ, Huibregtse BA, Stejskal EA, et al. Vascular response to a third generation everolimus-eluting stent. EuroIntervention. 2010; 6: 512-519.
19. Hou D, Huibregtse BA, Eppihimer MJ, et al. Fluorocopolymer-coated nitinol self-expanding low dose paclitaxel-eluting stent: pharmacokinetics and vascular biology responses in porcine iliofemoral model. EuroIntervention. 2016. In press.
20. Chin-Quee SL, Hsu SH, Nguyen-Ehrenreich KL, et al. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. Biomaterials. 2010; 31: 648-657.
21. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010; 3: 267-276.
22. Mewissen MW., Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vasc Interv Radiol. 2004; 7: 2-5.
23. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006; 13: 701-710.
24. Dearing DD, Patel KR, Compoginis JM, et al. Primary stenting of the superficial femoral and popliteal artery. J Vasc Surg. 2009; 50: 542-547.
25. Dick P, Wallner H, Sabeti S, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009; 74: 1090-1095.
26. Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015; 373: 145-153.
27. Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011; 54: 394-401.
28. Dake MD, Scheinert D, Tepe G, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011; 18: 613-623.
29. Iida O, Takahara M, Soga Y, et al. One-year results of the ZEPHYR (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery) registry: predictors of restenosis. JACC Cardiovasc Interv. 2015; 8: 1105-1112.